Wedelolactone
Wedelolactone inhibits adipogenic differentiation through ERK pathway, may be a novel inhibitory effect on adipogenic differentiation in hAMSCs. (In Vitro) :Wedelolactone (0-5 μg/mL; 0-21 d) enhances bone marrow mesenchymal stem cells (BMSC) differentiation towards osteoblasts.Wedelolactone (0-6 μg/mL; 0-9 d) inhibits GSK3β activity and increases β-catenin and runx2 nuclear accumulation in BMSC, and inhibits the effect of RANKL.Wedelolactone (0-5 μg/ml; 60 min) inhibits GSK3β activity and proves GSK3β is the target of wedelolactone.Wedelolactone (0-5 μg/ml; 6 d) inhibits c-src, c-fos and cathepsin k expression level. (In Vivo) :Wedelolactone (10 mg/kg; i.p. every 2 days for 4 weeks) decreases bone volumn and trabecular number at the femur after ovarietomy, and prevents the VOX-induced bone loss.
Product Specifications
CAS Number
524-12-9
Product Name Alternative
IKK Inhibitor II
Purity
>98% (HPLC)
Solubility
Soluble in Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Smiles
O=C1C2=C (OC3=CC (O) =C (O) C=C32) C4=C (O) C=C (OC) C=C4O1
Molecular Formula
C16H10O7
Molecular Weight
314.3
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
6H-Benzofuro (3,2-c) (1) benzopyran-6-one, 1,8,9-trihydroxy-3-methoxy-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TRNAY17P sgRNA CRISPR Lentivector (Human) (Target 1)
4930403N07Rik sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)
Rabbit Monoclonal Transglutaminase 2/TGM2 Antibody (013)